Parabilis Sets Biotech IPO Record
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
Clinical Scorecard: Parabilis Sets Biotech IPO Record
At a Glance
Category Detail
Condition Cancer and related conditions Key Mechanisms Stabilized helical peptides targeting protein modulation Target Population Patients with desmoid tumors, familial adenomatous polyposis, hepatocellular carcinoma, and other solid tumors with Wnt pathway-activating mutations Care Setting Clinical-stage biotechnology
Key Highlights
Raised $670 million in IPO, setting a new biotech listing record on Nasdaq Sold 33.5 million shares at $20 per share, trading under ticker PBLS Private placement with Regeneron for 4,166,666 shares at $18 per share Total expected gross proceeds of approximately $745 million Developing zolucatetide targeting beta-catenin in the Wnt/beta-catenin pathway Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with specific solid tumors and genetic conditions
Zolucatetide is in development for multiple indications related to Wnt pathway mutations
Clinical Best Practices
Utilize stabilized helical peptides for difficult-to-drug protein targets Consider collaboration opportunities for advancing clinical programs Related Resources & Content
